Inspired by their success and considering the association between ANKL and EBV infection, we integrated PD-1 monoclonal antibodies as immunotherapy into chemotherapy regimens as both induction and maintenance therapies for ANKL. This evidence concerns the gene PDCD1 and Epstein-Barr virus infection.